Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Project Context and Scope In September 2026 IOM in cooperation with Austrian Federal Chancellery will launch the Skills Mobility Partnership “EAGLE” between Austria and Egypt. The project will contribute to the deepening of economic cooperation and
Requisition ID: 7839 Grade: L3 Country: Austria Duty Station: Vienna Category: Professional and Higher Type of Job Posting: Internal and External Employment Type: Staff-Full-time Appointment Type: Fixed Term - 200 series Indicative Minimum Net Annual Salary: